Gilead Sciences and Genesis Therapeutics Form Strategic Partnership
Overview
Gilead Sciences and Genesis Therapeutics have announced a strategic partnership aimed at discovering and developing innovative small molecule therapies across multiple disease targets.
Gilead Generative AI
Gilead Generative AI, combined with science, people, and other new technologies, offers the potential to accelerate the identification of molecules for challenging disease targets.
Gilead on Partnership
Gilead is excited to partner with Genesis to explore their AI platform and develop new therapies to meet significant unmet medical needs.
Genesis AI Platform
Genesis AI platform is specifically designed to tackle such challenges and make drug discovery for hard-to-reach targets possible.
Genesis is excited to combine our expertise in AI with Gilead's strong research and development capabilities to develop breakthrough treatments for patients.
Post Collaboration
Through this collaboration, Genesis will use its cutting-edge AI platform, GEMS (Genesis Exploration of Molecular Space), to help design and optimise molecules for targets selected by Gilead.
Genesis is at the forefront of using generative and predictive artificial intelligence (AI) technology to tackle difficult-to-treat targets.
The companies will work closely on preclinical research, with Gilead retaining exclusive rights to advance any successful compounds into clinical development and, potentially, to market them.
Terms of Agreement
As part of the agreement, Genesis will receive an initial payment of $35 million for work on three targets.
Gilead also has the option to select more targets, for which it will pay an additional fee per target.
Genesis could receive further payments based on preclinical, development, regulatory, and commercial milestones.
If Gilead successfully markets any products developed through the collaboration, Genesis will be eligible for tiered royalties on net sales.
This deal is expected to reduce Gilead's 2024 earnings per share by approximately $0.02, both under GAAP and non-GAAP accounting measures.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!